NeuroXense
Develops a pre-clinical, tear-based Parkinson's diagnostic platform and a personalised follow-up model.
The record
- Vertical
- Imaging & Diagnostics
- Sub-segment
- Parkinson's biomarkers
- Product type
- Diagnostics
- Stage
- Pre-seed
- Headquarters
- Argentina
- Region
- Latin America
What they do
NeuroXense is an Argentina-based company developing a non-invasive diagnostic platform for Parkinson's disease based on tear samples. Its proprietary aptamer-based approach is intended to detect biomarkers, with a machine learning model for personalised follow-up. The work is pre-clinical, and the company says its next step in 2027 is working with real tears from patients. Its business model is B2B2B. Camila Feltrin is co-founder and CEO.
History and progression
How NeuroXense got here, step by step.
12 November 2026
PITCH semi-final
NeuroXense was one of nine startups in the PITCH semi-final on Centre Stage at Web Summit Lisbon 2026. It did not reach the final.
Sources and coverage
November 2026
Web Summit: NeuroXense appearance and pre-seed fundraising15 November 2026
The HealthTech Signal: Web Summit 2026 health tech
Related companies